Aytu refinances $15M term loan to $13M at ~12.4%, saving $1.3M interest

AYTU BIOPHARMA, INC

New $13M Eclipse term loan at SOFR+7% (~12.4%), replacing $15M Avenue loan at ~15.9%.
Interest rate reduced ~350 bps, saving ~$1.3M over loan life; maturity extended to June 2028.
Revolving credit facility extended to June 2028 with max borrowing capacity increased to $14.5M.
Received $3.5M from exercise of 2.17M warrants at $1.59; $2M used to pay down term loan.
Shares outstanding 5,972,327 as of June 18, 2024.

item 1.01 item 2.03 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.